ResMed (NYSE:RMD) said today that it closed the $750 million acquisition of MatrixCare and its post-acute-care software. The San Diego-based respiratory care giant said it funded the buyout, which represents a 25x EBITDA multiple, using its credit facility. Bloomington, Minn.-based MatrixCare put up sales of $122 million last year, ResMed said. “We’re all excited to have quickly closed this important […]
ResMed to pay $750m for MatrixCare
ResMed (NYSE:RMD) said today that it agreed to pay $750 million to acquire MatrixCare and its post-acute-care software. The San Diego-based respiratory care giant said it plans to fund the buyout, which represents a 25x EBITDA multiple, using its credit facility. Bloomington, Minn.-based MatrixCare put up sales of $122 million last year, ResMed said. “The acquisition of MatrixCare is […]
ResMed’s fiscal Q1 tops forecast
ResMed (NYSE:RMD) yesterday reported fiscal first-quarter results that beat the consensus forecast. The San Diego-based respiratory device maker posted profits of $105.7 million, or 73¢ per share, on sales of $588.3 million for the three months ended Sept. 30, for bottom-line growth of 22.8% on sales growth of 12.3% compared with fiscal Q1 2018. Adjusted to […]
ResMed touts German win in continued Fisher & Paykel patent spat
ResMed (NYSE:RMD) yesterday touted a win in a German patent spat over masks used with continuous positive airway pressure machines with competitor Fisher & Paykel Healthcare (NZE:FPH). San Diego-based ResMed said that a trial court ruling from Germany’s Munich District Court found that Fisher & Paykel’s Simplus full face and Eson 2 nasal mask head gear infringes […]
ResMed files suits in continued patent spat with Fisher & Paykel
ResMed (NYSE:RMD) said late last week it filed a patent infringement petition with the US International Trade Commissions against competitor Fisher & Paykel Healthcare (NZE:FPH) in a continued spat between the companies. San Diego-based ResMed said they also filed a new lawsuit against Fisher & Paykel seeking monetary damages related to patent infringement from the company, as […]
ResMed ventilator now has autoEPAP
ResMed (NYSE:RMD) has added autoEPAP to its Astral life support ventilator in the United States. AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway. It’s an option when in Astral’s iVAPS (intelligent volume-assured pressure support) mode that automatically adapts to a patient’s […]
ResMed shares down as FY2018 earnings show shrinking profits
Shares in ResMed (NYSE:RMD) have fallen today after the medical device maker posted fourth quarter and full fiscal year 2018 earnings that topped expectations on the Street, but showed full year profits decline when compared to 2017. The San Diego-based company posted profits of $109.8 million, or 76¢ per share, on sales of $623.6 million for […]
ResMed, Google’s Verily ink sleep-apnea-focused joint venture deal
ResMed (NYSE:RMD) and Google (NSDQ:GOOG) life sciences company Verily said today they inked a new joint venture deal aiming to develop software solutions to improve diagnosis, treatment and care for sleep apnea and other breathing related sleep disorders. The new US-based joint venture will use sleep apnea knowledge from San Diego-based ResMed and Verily’s data analytics technologies in its […]
ResMed to acquire home and hospice software dev HealthcareFirst
ResMed (NYSE:RMD) said today it inked a deal to acquire healthcare software developer HealthcareFirst for an undisclosed amount. The soon-to-be acquired company develops software and services for both home health and hospice agencies, San Diego-based ResMed said. Offerings include electronic health record software, billing and coding services and advanced analytics for home and hospice settings. “Joining […]
ResMed touts cost efficiency in home oxygen, non-invasive ventilation therapy study
ResMed (NYSE:RMD) today released data from two clinical analyses exploring combined home oxygen therapy and non-invasive ventilation therapy for patients with persistent hypercapnia following a life-threatening exacerbation of chronic obstructive pulmonary disorder, touting an increase in cost efficiency with the combined therapy. Results from the two studies, performed in the U.K. and the US, were presented […]
ResMed posts Street-beating Q3
Shares in ResMed (NYSE:RMD) have fallen today despite the respiratory device maker beating expectations on Wall Street with its fiscal year 2018 third quarter earnings release. The San Diego, Calif.-based company posted profits of $110.1 million, or 76¢ per share, on sales of $591.6 million for the three months ended March 31, for bottom-line growth of […]
- 1
- 2
- 3
- …
- 9
- Next Page »
MassDevice Network
@MassDevice
LinkedIn